WO2022014848A1 - 프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제 및 그의 제조방법 - Google Patents
프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제 및 그의 제조방법 Download PDFInfo
- Publication number
- WO2022014848A1 WO2022014848A1 PCT/KR2021/006381 KR2021006381W WO2022014848A1 WO 2022014848 A1 WO2022014848 A1 WO 2022014848A1 KR 2021006381 W KR2021006381 W KR 2021006381W WO 2022014848 A1 WO2022014848 A1 WO 2022014848A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- layer
- pharmaceutical combination
- proton pump
- pump inhibitor
- mixture
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 150
- 238000009472 formulation Methods 0.000 title claims abstract description 102
- 229940126409 proton pump inhibitor Drugs 0.000 title claims abstract description 46
- 239000000612 proton pump inhibitor Substances 0.000 title claims abstract description 46
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 title claims abstract description 30
- 229940069428 antacid Drugs 0.000 title claims abstract description 29
- 239000003159 antacid agent Substances 0.000 title claims abstract description 29
- 230000001458 anti-acid effect Effects 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims description 29
- 239000002131 composite material Substances 0.000 title abstract description 19
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims abstract description 21
- 239000000347 magnesium hydroxide Substances 0.000 claims abstract description 21
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 11
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 11
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000314 lubricant Substances 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 23
- 229960004770 esomeprazole Drugs 0.000 claims description 20
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims description 20
- 239000011230 binding agent Substances 0.000 claims description 17
- 238000004090 dissolution Methods 0.000 claims description 15
- 239000007884 disintegrant Substances 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 12
- 239000011812 mixed powder Substances 0.000 claims description 12
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical group CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 11
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 238000007922 dissolution test Methods 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 229960003174 lansoprazole Drugs 0.000 claims description 4
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229960003943 hypromellose Drugs 0.000 claims description 3
- 229960000381 omeprazole Drugs 0.000 claims description 3
- 229960005019 pantoprazole Drugs 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229960004157 rabeprazole Drugs 0.000 claims description 3
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000003607 modifier Substances 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 118
- 239000003826 tablet Substances 0.000 description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 10
- 210000004211 gastric acid Anatomy 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000000354 decomposition reaction Methods 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229960000913 crospovidone Drugs 0.000 description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000007942 layered tablet Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 239000002702 enteric coating Substances 0.000 description 4
- 238000009505 enteric coating Methods 0.000 description 4
- 229920001903 high density polyethylene Polymers 0.000 description 4
- 239000004700 high-density polyethylene Substances 0.000 description 4
- 238000010030 laminating Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 2
- 108010083204 Proton Pumps Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229960000816 magnesium hydroxide Drugs 0.000 description 2
- 235000012254 magnesium hydroxide Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- It relates to a pharmaceutical combination preparation comprising a proton pump inhibitor and an antacid, and more particularly, it is possible to prevent decomposition of the proton pump inhibitor in the stomach and improve stability from gastric acid without enteric coating, while improving drug quality, physical stability, and It relates to a pharmaceutical combination formulation with improved productivity and a method for manufacturing the same.
- Proton pump inhibitors are drugs that inhibit the proton pump (H+/K+-ATPase) of parietal cells to suppress the production of hydrochloric acid and weaken the acidity in the digestive system. It shows its medicinal effect in pharyngeal reflux disease or peptic ulcer disease.
- a benzimidazole-based compound or a salt thereof is used as a treatment for peptic ulcer having a proton pump inhibitory action, and examples thereof include omeprazole, lansoprazole, rabeprazole, pantoprazole, esomeprazole, and the like.
- proton pump inhibitors have a problem in that they are easily decomposed or deformed under acidic conditions.
- lansoprazole is poorly soluble in water and is very unstable in acid, so it is easily decomposed in gastric juice, an acidic solution, and thus does not exhibit the desired pharmacological effect.
- esomeprazole has a problem in that the physical properties and storage stability of the free base itself are not good, and in particular, stability in acidic and neutral environments is significantly lower than stability in alkaline environments. It is highly affected and has poor stability, especially in acidic environments.
- Korean Patent Application Laid-Open No. 10-2008-0005575 proposes a method for stabilizing a benzimidazole-based proton pump inhibitor by coating it with an enteric polymer in order to improve the stability.
- One aspect is to provide a pharmaceutical combination formulation comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof and an antacid, with improved pharmaceutical quality, physical stability, and productivity.
- Another aspect is to provide a method for preparing a pharmaceutical combination comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof and an antacid.
- One aspect is a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof and a lubricant as an active ingredient; and a second layer comprising an antacid selected from magnesium hydroxide, magnesium oxide, and mixtures thereof as an active ingredient; provides a pharmaceutical combination formulation comprising.
- Another aspect is to prepare a first layer mixture comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof and a lubricant as an active ingredient;
- Preparing a second layer mixture comprising an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof as an active ingredient;
- It provides a method for manufacturing a pharmaceutical combination preparation comprising; tableting the first layer mixed powder and the second layer mixed powder.
- the pharmaceutical combination formulation according to an aspect may improve tabletting disorders, improve drug quality and productivity, and improve physical stability.
- the complex formulation can prevent the decomposition of the proton pump inhibitor by gastric acid without enteric coating, and the proton pump inhibitor is rapidly eluted and absorbed in the body, and the drug effect is not delayed.
- the manufacturing method according to an aspect can increase manufacturing productivity by improving tableting disorder, quality, and stability of the composite formulation.
- One aspect is a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof and a lubricant as an active ingredient; and a second layer comprising an antacid selected from magnesium hydroxide, magnesium oxide, and mixtures thereof as an active ingredient; provides a pharmaceutical combination formulation comprising.
- the pharmaceutical combination preparation is formulated in a certain shape by mixing and molding the active ingredient and the pharmaceutical additive.
- the physicochemical properties of the active ingredient or the composition of the combined preparation including the active ingredient and the pharmaceutical additive depends on the quality of the drug. , physical stability, and productivity.
- Tableting disorders that may occur during the manufacture of pharmaceutical combination formulations include sticking, capping, laminating, chipping, or picking. of course, it can cause a decrease in productivity as it makes continuous production work impossible.
- a pharmaceutical composition including a binder in the first layer for the purpose of time lag release of PPI and antacid, that is, prior release of PPI
- the occurrence of tableting disorders may increase.
- the tableting disorder can be remarkably improved by granulating the first layer and controlling the content of the lubricant.
- the physical stability can be remarkably improved by adjusting the length ratio of the long axis and the short axis of the combined preparation.
- the term “sticking” refers to a phenomenon in which powder adheres to the surface of a punch in the manufacturing process and a groove is formed on the surface of the tablet. During tableting, the powder may adhere to the surface of the upper punch or lower punch, resulting in grooves on the tablet surface.
- the term “capping” refers to a phenomenon in which the upper portion of the tablet is peeled off in the shape of a hat.
- the term “laminating” refers to a phenomenon in which the tablet is peeled off in layers.
- the term “picking” refers to a case in which uneven spots appear on the surface of the tablet.
- Tableting disorders that may occur during manufacture of the combination formulation according to one embodiment may include sticking, capping, laminating, and picking.
- the first layer may be prepared from a mixture containing a proton pump inhibitor or a pharmaceutically acceptable salt thereof and a lubricant.
- the mixture may further include other pharmaceutical additives.
- the first layer may further include a binder.
- the first layer may further include any one binder selected from hydroxypropyl cellulose, hypromellose, polyvinylpyrrolidone, pregelatinized starch, and any combination thereof.
- the content of the binder included in the first layer of the composite formulation is about 55% or more for 60 minutes of dissolution test measurement, preventing the initial release of the proton pump inhibitor included in the first layer of the composite formulation to prevent acid degradation in the stomach
- a proton pump inhibitor may be included in an amount sufficient to elute.
- the content of the binder included in the first layer of the composite formulation may be included in an amount exceeding about 2 parts by weight and less than 6 parts by weight based on 1 part by weight of the disintegrant included in the first layer.
- the binder included in the first layer of the combination formulation is about 2 to 5.5 parts by weight, such as about 2.5 to 5 parts by weight, or about 2 to 5 parts by weight, based on 1 part by weight of the disintegrant included in the first layer. may be included as a part.
- the binder By including the binder in the above range, it is possible to secure the time lag release for each layer of the proton pump inhibitor and the antacid present in different layers in the combination formulation, so that the antacid in the combination formulation is released first, and then the proton pump inhibitor is released. , thereby preventing gastric acid degradation of the drug and obtaining a desired dissolution rate of the proton pump inhibitor.
- the first layer including the proton pump inhibitor and the lubricant may be included in the form of granules.
- the granules may be dry granules or wet granules, preferably dry granules.
- the granules may be manufactured by a method of compacting.
- the compacting may be manufactured using a roller compactor.
- the compacting may be performed by pressing under conditions of a hydraulic pressure of about 1 to 7 MPa, a feeder speed of about 1 to 10 rpm, and a roller speed of about 0.5 to 5 rpm to form flakes.
- granules can be obtained by pulverizing and sieving the prepared compact.
- the sieve may be sieved with a sieve size of about 0.5 to 5 mm.
- the pharmaceutical combination formulation includes the first layer in the form of granules, it is possible to significantly improve productivity by reducing tableting disorders that may occur during the manufacture of the composite formulation including sticking.
- the term “glidant” refers to a substance used to provide slippage and reduce friction during formulation manufacturing.
- the lubricant improves the fluidity of the powder and granular material to increase the filling ability into the die, which is the lower part of the tableting machine, and between the powder and granular material, and between the upper and lower punch-die of the tableting machine and the powder and granular material. Friction can be reduced to facilitate compression and release of the tablet.
- the lubricant is sodium stearyl fumarate, stearic acid, stearate, talc, corn starch, carnauba wax, light anhydrous silicic acid, magnesium silicate, synthetic aluminum silicate, hydrogenated oil, white wax, titanium oxide, microcrystalline cellulose, macrogol 4000 and 6000, It may be one or more selected from the group consisting of isopropyl myristate, calcium hydrogen phosphate, talc, and any mixtures thereof, but is not limited thereto.
- the lubricant included in the first layer of the combination formulation may be sodium stearyl fumarate, magnesium stearate, or any combination thereof.
- the lubricant included in the first layer of the pharmaceutical combination formulation is about 1.5 to 7% by weight, specifically about 2 to 6.5% by weight, more specifically about It may be included in 3 to 6% by weight.
- the lubricant may be included in an amount of about 3 to 5.5 wt%, about 3 to 5 wt%, or about 3.5 to 5.5 wt%, based on the total weight of the first layer.
- the pharmaceutical combination formulation includes a lubricant in the above range, it is possible to significantly improve productivity by reducing tableting disorders that may occur during the manufacturing of the combination formulation including sticking.
- the total weight of the second layer when the total weight of the first layer is 1 part by weight, the total weight of the second layer may be included in an amount of about 4 parts by weight or less, and more specifically, it may include about 3.5 parts by weight or less. .
- the second layer of the composite formulation when the total weight of the first layer is 1 part by weight, the second layer of the composite formulation may be included in an amount of about 3.25 parts by weight or less.
- the second layer may be about 1 to 4 parts by weight.
- the first layer and the second layer of the pharmaceutical combination formulation may be included in a weight ratio of about 1:4 to 1:1 or about 1:3.5 to 1:1.
- the weight ratio of the first layer to the second layer may be about 1:3.25 to 1:1.
- the pharmaceutical combination formulation includes the weight or weight ratio of the first layer and the second layer in the above range, various tableting disorders including sticking are reduced, the formulation uniformity of the combination formulation is remarkably improved, and the quality of the drug and productivity can be improved. If it is out of the above weight ratio, the content uniformity may be reduced due to the difference in mass of each layer.
- the combination preparation may be a tablet or capsule.
- the composite formulation may be a multi-layered tablet such as a double-layered tablet or a three-layered tablet, or a double-layered tablet (nucleated tablet) form, preferably a double-layered tablet.
- Such tablets may, for example, have a hardness of about 10 kP to about 20 kP.
- the pharmaceutical combination preparation may be oval, circular, semi-circular, or square, preferably oval.
- the pharmaceutical combination formulation according to one embodiment contains magnesium hydroxide or magnesium oxide used as an antacid as one of the active ingredients in a high ratio, tablet breakage is easy to occur.
- a two-layer tablet consisting of an esomeprazole-containing layer and a magnesium hydroxide-containing layer is taken, the disintegration and release of the magnesium hydroxide-containing layer in the intragastric environment is greater. can do.
- binders may be added to maintain the structure of the formulation and reduce breakage.
- the use of a binder in the magnesium hydroxide-containing layer limits the prior release of the antacid, the antacid is released faster than the proton pump inhibitor, thereby neutralizing gastric acid, thereby achieving the purpose of preventing the decomposition of the proton pump inhibitor in the stomach. make it impossible Therefore, even if tablet breakage occurs, there is a limit to the use of a binder in the magnesium hydroxide-containing layer.
- the present inventors studied the form of a formulation capable of improving the physical stability of a pharmaceutical formulation, and confirmed that it is possible to improve formulation stability and reduce breakage by controlling the ratio of the major axis and minor axis length.
- long axis refers to the longest length of the combination preparation, such as a tablet, according to an embodiment when viewed from above.
- Short refers to the shortest length when viewed from the top of the combination preparation, such as a tablet, according to an embodiment.
- the composite formulation has two orthogonal axes of the same or different length when projected onto a flat surface, and the longer length may be the major axis and the shorter length may be the shorter length.
- the lengths of the two orthogonal axes are the same, one may be the major axis and the other may be the short axis.
- the pharmaceutical combination formulation according to one embodiment significantly improves the physical stability of the pharmaceutical formulation by controlling the length of the long axis and the minor axis, and reduces damage that may occur in the process of handling, transporting, or preserving the pharmaceutical product. It can improve quality and productivity.
- the combination preparation may have the same length ratio of the major axis and the minor axis, or may have different forms.
- the combination formulation may have a major axis:short axis length ratio of about 2.35:1 or less.
- the length of the major axis of the combination formulation may not be greater than about 2.3 times the length of the minor axis.
- the length of the major axis of the combination formulation may not be greater than about 2.25 times the length of the minor axis.
- the combination formulation may have a length ratio of the long axis to the short axis of about 1:1 to 2.3:1.
- the combination formulation may have a length ratio of the long axis: the short axis of about 1:1 to 2.25:1.
- the combination preparation may be a double-layer tablet having a length ratio of the long axis to the short axis of about 1:1 to 2.3:1.
- the combined formulation may have a major axis of about 14 to 16 mm, and a minor axis of about 7.2 to 8 mm.
- the composite formulation having a long axis:short axis length ratio in the above range may have a breakage rate of about 10% or less.
- the combination formulation according to one embodiment may have a breakage rate of about 0%.
- failure rates may occur greater than about 10%, greater than about 15%, or about 15-50%.
- a combination formulation having a length ratio of long axis: short axis of 2.36:1 may have a breakage rate of about 16.7%
- a combination formulation having a length ratio of 2.5:1 may have a breakage rate of about 30%.
- the breakage rate can be measured by a method of counting the number of broken tablets after placing 30 tablets of the composite formulation into a high-density polyethylene (HDPE) bottle and dropping 10 times from a height of 150 cm.
- HDPE high-density polyethylene
- the proton pump inhibitor may be any one selected from the group consisting of esomeprazole, omeprazole, lansoprazole, rabeprazole, pantoprazole, and any combination thereof.
- the proton pump inhibitor included in the first layer of the pharmaceutical combination formulation may include about 5 to 25% by weight based on the total weight of the first layer.
- the pharmaceutically acceptable salt of the proton pump inhibitor is any pharmaceutically acceptable salt that can be conventionally used in the art, for example, magnesium (Mg) salt, strontium (Sr) salt, lithium salt, sodium A metal salt or ammonium salt such as salt, potassium salt, calcium salt, etc. may be used, but the present invention is not limited thereto.
- the proton pump inhibitor or a pharmaceutically acceptable salt thereof may be provided in the form of an anhydride or a hydrate, such as a monohydrate, a dihydrate, or a trihydrate.
- the antacid selected from magnesium hydroxide, magnesium oxide, and mixtures thereof included in the second layer of the pharmaceutical combination formulation may include about 50 to 90% by weight based on the total weight of the second layer. .
- the first layer may further include any one selected from a diluent, a binder, a disintegrant, and any mixture thereof.
- the second layer may further include any one selected from a diluent, a disintegrant, a fluidizing agent, a lubricant, and any mixture thereof.
- the term “diluent” refers to a substance added to increase the dosage of a formulation. Unlike active pharmaceuticals, it is a substance used to increase safety while being safe, and is also referred to as an excipient.
- the diluent may be at least one selected from the group consisting of microcrystalline cellulose, lactose, dextrin, mannitol, sorbitol, starch, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, calcium carbonate, saccharides, and mixtures thereof, but is not limited thereto.
- the diluent may be microcrystalline cellulose.
- the diluent included in the first layer of the pharmaceutical combination formulation may include about 50 to 90% by weight based on the total weight of the first layer.
- the diluent included in the second layer of the pharmaceutical combination formulation may include about 7 to 40% by weight based on the total weight of the second layer.
- the term “binder” refers to a substance added to impart certain adsorption or solidification to a mixture.
- the binder may be at least one selected from the group consisting of hydroxypropylcellulose, hypromellose (hydroxypropyl methylcellulose), polyvinylpyrrolidone, pregelatinized starch, and any mixtures thereof, limited thereto. it is not going to be
- the binder may be hydroxypropyl cellulose.
- the binder included in the first layer of the pharmaceutical combination formulation may include about 1 to 20% by weight based on the total weight of the first layer.
- the term “disintegrant” refers to a substance added to expand the formulation so that the solid is disintegrated before it is absorbed.
- the disintegrant may be at least one selected from the group consisting of crospovidone, sodium starch glycolate, and mixtures thereof, but is not limited thereto.
- the disintegrant may be crospovidone.
- the disintegrant included in the first layer of the pharmaceutical combination may be included in an amount of about 1 to 5% by weight based on the total weight of the first layer.
- the content of the disintegrant included in the first layer of the composite formulation prevents acid decomposition in the stomach of the proton pump inhibitor included in the first layer of the composite formulation, and about 55% or more of the proton pump inhibitor is present in the dissolution test for 60 minutes. It may be included in an amount sufficient to elute.
- the disintegrant included in the second layer of the pharmaceutical combination may be included in an amount of about 1 to 5% by weight based on the total weight of the second layer.
- the term “glidant” refers to a substance that affects the flow of a formulation.
- the fluidizing agent may be at least one selected from the group consisting of colloidal silicon dioxide, silicon dioxide, talc, and mixtures thereof, but is not limited thereto.
- the glidant may be colloidal silicon dioxide.
- the fluidizing agent included in the second layer of the pharmaceutical combination formulation may include about 1 to 5% by weight based on the total weight of the second layer.
- the lubricant component included in the second layer of the composite formulation is the same as in the first layer.
- all of the lubricants included in the first and second layers of the composite formulation may be sodium stearyl fumarate.
- the lubricant included in the second layer of the pharmaceutical combination formulation may include about 0.1 to 3% by weight based on the total weight of the second layer.
- any pharmaceutical additives that can be conventionally used in the art may be included in an appropriate amount.
- one or more additives selected from the group consisting of surfactants, antioxidants, preservatives, stabilizers, flavoring agents, colorants, solubilizers, pH adjusting agents, coating agents, and any combination thereof may be further included, The present invention is not limited thereto.
- the proton pump inhibitor and the antacid present in different layers may exhibit time-lag release for each layer.
- the antacid present in the layer containing the antacid is first released to increase the pH in the stomach, and then the proton pump inhibitor present in the layer containing the proton pump inhibitor is released to neutralize the acidic environment in the stomach, It can prevent the breakdown of proton pump inhibitors by gastric acid.
- the combination preparation is a pharmaceutical combination preparation containing a proton pump inhibitor and an antacid as an active ingredient, and the antacid rapidly neutralizes gastric acid. , and the proton pump inhibitor is quickly eluted and absorbed in the body, and the drug effect is not delayed.
- the combination formulation is a mixture of 150 mL of 0.1N HCl and 450 mL of purified water at a rotation speed of 75 rpm and 37 ⁇ 0.5° C. according to the second method paddle method of the United States Pharmacopoeia (USP) dissolution test item.
- the dissolution rate of the proton pump inhibitor for 60 minutes may be about 55% or more.
- the dissolution rate of the combination formulation may be about 70% or more.
- Another aspect is to prepare a first layer mixture comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof and a lubricant as an active ingredient;
- preparing a second layer mixture comprising an antacid selected from magnesium hydroxide, magnesium oxide, and a mixture thereof;
- It provides a method for manufacturing a pharmaceutical combination preparation comprising the step of tableting the first layer mixed powder and the second layer mixed powder.
- preparing the first layer mixture may include a granulation (compacting) process.
- the compacting method is the same as described in the pharmaceutical combination formulation.
- the numerical range indicated using the term “to” includes the range indicated by the lower limit and the upper limit of the numerical values described before and after the term “to”, respectively.
- the expression "about”, or approximately”, etc., means that the referenced value may vary to some extent. For example, the value may be 10%, 5%, 2%, or 1
- "about 5" is meant to include any value between 4.5 and 5.5, between 4.75 and 5.25, or between 4.9 and 5.1, or between 4.95 and 5.05. .
- Esomeprazole, microcrystalline cellulose and hydroxypropyl cellulose, and crospovidone were taken and mixed for 10 minutes.
- the mixture was compressed using a roller compactor (TF-1-A60, Freund vector) under the conditions of a hydraulic pressure of 2 MPa, a feeder speed of 5 rpm, and a roller speed of 1 rpm to form flakes. Then, it was established through a sieve of 1.0 mm sieve size.
- sodium stearyl fumarate as a lubricant was added and mixed for 5 minutes to prepare a final mixture of the upper layer.
- Magnesium hydroxide, microcrystalline cellulose, and crospovidone were taken and mixed for 10 minutes.
- the mixture was compressed using a roller compactor (TF-1-A60, Freund vector) under the conditions of a hydraulic pressure of 5 MPa, a feeder speed of 5 rpm, and a roller speed of 1 rpm to form flakes. Then, it was established through a sieve of 2.0 mm sieve size. After adding colloidal silicon dioxide as a fluidizing agent to the sizing material and mixing for 5 minutes, sodium stearyl fumarate as a lubricant was added and mixed for 5 minutes to prepare a final mixed part of the lower layer.
- Double-layer tablets (hardness of about 17 kp) were prepared by tableting with a tableting machine (Autotab-200TR, ichihashi seiki) and an oval punch with a width of 15.5 mm and a length of 7.5 mm with the final mixed powder of the upper layer and the final mixed powder of the lower layer.
- a tableting machine Autotab-200TR, ichihashi seiki
- compositions of the pharmaceutical combination formulations according to Examples 1 to 3 are shown in Table 1 below.
- Examples 4 to 5 were produced by changing the punch used to produce a two-layer tablet with the same hardness as Example 1 of about 17 kp with the upper final mixed powder and the lower final mixed powder of Example 1.
- Example 4 a double-layer tablet was prepared by tableting with an oval punch having a width of 14.0 mm and a length of 8.0 mm.
- Example 5 a two-layer tablet was prepared by tableting with an oval punch having a width of 16.0 mm and a length of 7.2 mm.
- Magnesium hydroxide, microcrystalline cellulose, and crospovidone were taken and mixed for 10 minutes.
- the mixture was compressed using a roller compactor (TF-1-A60, Freund vector) under the conditions of a hydraulic pressure of 5 MPa, a feeder speed of 5 rpm, and a roller speed of 1 rpm to form flakes, followed by 2.0 mm It was established through a sieve the size of a sieve.
- colloidal silicon dioxide as a fluidizing agent to the sizing material and mixing for 5 minutes
- sodium stearyl fumarate as a lubricant was added and mixed for 5 minutes to prepare a final mixed part of the lower layer.
- a double-layer tablet was prepared using a tableting machine (Autotab-200TR, ichihashi seiki) as in Example 1 using the uppermost mixed powder and the final mixed powder of the lower layer.
- compositions of the pharmaceutical combination formulations according to Comparative Examples 1 to 6 are shown in Tables 2 and 3 below.
- Test Example 1 Evaluation of tableting disorder, confirmation of occurrence of sticking
- sodium stearyl fumarate was used as a lubricant.
- the degree of tableting failure was determined based on the number of tablets produced up to the time of sticking.
- the final mixture of the upper layer of Comparative Example 1 Bet 3 was a simple mixing process that did not go through granulation, followed by a direct pressing process to produce a two-layer tablet.
- Comparative Example 4 In the case of Comparative Example 4 in which sodium stearyl fumarate was reduced to about 1.3 wt%, sticking occurred, but it was confirmed that it was improved compared to Comparative Examples 1 to 3 produced by the direct pressing process. Therefore, it can be confirmed that tableting disorders including sticking are improved when the compacting process is applied.
- Test Example 2 Formulation uniformity test of esomeprazole
- Example 1 Example 3, Example 3, and each of 10 double-layer tablets prepared in Comparative Examples 5 to 6 were subjected to a content uniformity test for formulation uniformity, and the results are shown in Table 5.
- UV absorbance spectrometer (measurement wavelength 302 nm)
- Two-layer tablets of Examples 1, 3, and Comparative Examples 5 to 6 were prepared using the final mixed part of the upper layer and the final mixed part of the lower layer having the same composition ratio, but the total content of the final mixed part of the upper layer was different.
- the flowability of the final mixed portion of the upper layer is the same, and only the weight ratio of the upper layer and the lower layer is different. From the above results, it can be confirmed that the difference in content uniformity is due to the weight ratio of the upper layer and the lower layer.
- Examples 1 and 3 in which the weight ratio of the upper layer: the lower layer was about 1:3.2 or less, had good content uniformity judgment values of 15 or less, but Comparative Examples 5 and 6 of 1:4 or more had an unsuitable judgment value of 15 or more. level was confirmed.
- double-layer tablet tableting even if the total weight is constant, the mass deviation of the upper layer may be affected by the mass deviation of the lower layer containing the antacid. The result received has been confirmed.
- the dissolution rate of esomeprazole from the formulations prepared in Examples 1 to 3 was evaluated under the following dissolution conditions and analysis conditions, and the results are shown in FIG. 1 .
- Eluate Take 2 tablets (80 mg as esomeprazole) and test in a mixture of 75 mL of 0.1N HCl and 225 mL of purified water.
- Dissolution time 5, 10, 15, 30, 45, 60 minutes
- phosphate buffer (pH 7.3) is 1 L of 1 mol/L sodium dihydrogen phosphate by mixing 10.5 mL of sodium dihydrogen phosphate and 60.0 mL of 0.5 mol/L disodium hydrogen phosphate, then adding water.)
- the eluate is a mixture of 0.1N HCl and purified water, and reproduces a mixture of gastric juice present in the stomach and water taken together for drug administration.
- the eluate is to confirm the degree of decomposition of esomeprazole due to the low pH in the stomach and the antacid power of the antacid when the formulations prepared in Examples 1 to 3 are taken.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (15)
- 유효성분으로서 프로톤 펌프 저해제 또는 이의 약학적으로 허용가능한 염 및 활택제를 포함하는 제1층; 및수산화마그네슘, 산화마그네슘, 및 이들의 혼합물 중에서 선택되는 제산제를 유효성분으로 포함하는 제2층;을 포함하는 약제학적 복합제제.
- 청구항 1에 있어서, 상기 프로톤 펌프 저해제 및 활택제를 포함하는 제1층은 과립 형태로 포함되는 것을 특징으로 하는 약제학적 복합제제.
- 청구항 1에 있어서, 상기 활택제는 제1층의 총 중량을 기준으로 1.5 내지 7 중량%로 포함되는 것을 특징으로 하는 약제학적 복합제제.
- 청구항 1에 있어서, 상기 제1층의 총 중량을 1 중량부로 할 때 상기 제2층의 총 중량은 4 중량부 이하로 포함되는 것을 특징으로 하는 약제학적 복합제제.
- 청구항 1에 있어서, 상기 제1층과 제2층은 1:4 내지 1:1의 중량비로 포함되는 것을 특징으로 하는 약제학적 복합제제.
- 청구항 1에 있어서, 상기 복합제제는 정제 또는 캡슐제인 것을 특징으로 하는 약제학적 복합제제.
- 청구항 1에 있어서, 상기 복합제제의 장축:단축 길이비가 1:1 내지 2.3:1인 이층정제인 것을 특징으로 하는 약제학적 복합제제.
- 청구항 1에 있어서, 상기 프로톤 펌프 저해제는 에스오메프라졸, 오메프라졸, 란소프라졸, 라베프라졸, 판토프라졸, 및 이들의 임의의 조합 중에서 선택되는 어느 하나인 것을 특징으로 하는 약제학적 복합제제.
- 청구항 1에 있어서, 상기 제1층은 희석제, 결합제, 붕해제, 및 이들의 임의의 혼합물 중에서 선택되는 어느 하나를 더 포함하는 것을 특징으로 하는 약제학적 복합제제.
- 청구항 1에 있어서, 상기 제2층은 희석제, 붕해제, 유동화제, 활택제, 및 이들의 임의의 혼합물 중에서 선택되는 어느 하나를 더 포함하는 것을 특징으로 하는 약제학적 복합제제.
- 청구항 1에 있어서, 상기 활택제는 푸마르산스테아릴나트륨, 스테아린산 마그네슘, 및 이들의 임의의 조합 중에서 선택되는 것을 특징으로 하는 약제학적 복합제제.
- 청구항 1에 있어서, 상기 제1층은 히드록시프로필셀룰로오스, 히프로멜로오스, 폴리비닐피롤리돈, 프리젤라틴화 전분, 및 이들의 임의의 조합 중에서 선택되는 어느 하나의 결합제를 더 포함하는 것을 특징으로 하는 약제학적 복합제제.
- 청구항 1에 있어서, 미국약전(USP) 용출시험 항목의 제2법 패들법에 따라 회전수 75 rpm, 37±0.5℃ 조건에서 0.1N HCl 150 mL와 정제수 450 mL을 혼화한 액에서 시험할 때, 60분 동안 프로톤펌프 저해제의 용출률이 55% 이상인 것을 특징으로 하는 약제학적 복합제제.
- 유효성분으로서 프로톤 펌프 저해제 또는 이의 약학적으로 허용가능한 염 및 활택제를 포함하는 제1층 혼합분을 제조하는 단계;수산화마그네슘, 산화마그네슘, 및 이들의 혼합물 중에서 선택되는 제산제를 유효성분으로 포함하는 제2층 혼합분을 제조하는 단계; 및상기 제1층 혼합분 및 제2층 혼합분을 타정하는 단계;를 포함하는 약제학적 복합제제의 제조방법.
- 청구항 14에 있어서, 상기 제1층 혼합분을 제조하는 단계는 과립화 공정을 포함하는 것을 특징으로 하는 약제학적 복합제제의 제조방법.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180061309.XA CN116133651A (zh) | 2020-07-14 | 2021-05-21 | 包括质子泵抑制剂和抗酸剂的药物复合制剂和其制备方法 |
BR112023000520A BR112023000520A2 (pt) | 2020-07-14 | 2021-05-21 | Formulação farmacêutica composta e método de preparação de uma formulação farmacêutica composta |
EP21841376.3A EP4166132A4 (en) | 2020-07-14 | 2021-05-21 | PHARMACEUTICAL COMPOSITE FORMULATION CONTAINING PROTON PUMP INHIBITOR AND ANTACID AND METHOD FOR THE PRODUCTION THEREOF |
US18/004,317 US20230248707A1 (en) | 2020-07-14 | 2021-05-21 | Pharmaceutical composite formulation comprising proton pump inhibitor and antacid, and method for preparing same |
MX2023000645A MX2023000645A (es) | 2020-07-14 | 2021-05-21 | Formulacion farmaceutica compuesta que comprende un inhibidor de bomba de protones y un antiacido, y un metodo para preparar la misma. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0087143 | 2020-07-14 | ||
KR1020200087143A KR102608889B1 (ko) | 2020-07-14 | 2020-07-14 | 프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제 및 그의 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022014848A1 true WO2022014848A1 (ko) | 2022-01-20 |
Family
ID=79554876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/006381 WO2022014848A1 (ko) | 2020-07-14 | 2021-05-21 | 프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제 및 그의 제조방법 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230248707A1 (ko) |
EP (1) | EP4166132A4 (ko) |
KR (1) | KR102608889B1 (ko) |
CN (1) | CN116133651A (ko) |
BR (1) | BR112023000520A2 (ko) |
MX (1) | MX2023000645A (ko) |
WO (1) | WO2022014848A1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0813424B1 (en) * | 1996-01-08 | 2002-11-20 | AstraZeneca AB | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate |
US20040248939A1 (en) * | 2001-08-31 | 2004-12-09 | Masae Sugaya | Stable pharmaceutical compositions comprising acid labile benzimidazoles |
KR20080005575A (ko) | 2005-04-28 | 2008-01-14 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 안정화 조성물 |
KR20150067777A (ko) * | 2013-11-29 | 2015-06-19 | 한미약품 주식회사 | 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제 |
KR20170136771A (ko) * | 2016-06-02 | 2017-12-12 | 동화약품주식회사 | 프로톤 펌프 저해제의 고체분산체 및 이를 포함하는 약제학적 조성물 |
KR101849125B1 (ko) * | 2016-12-12 | 2018-04-16 | 동화약품주식회사 | 프로톤 펌프 저해제를 포함하는 고체 분산체, 이의 제조방법 및 이를 포함하는 구강 붕해정 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040166162A1 (en) * | 2003-01-24 | 2004-08-26 | Robert Niecestro | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
AU2009215514B9 (en) * | 2008-02-20 | 2014-01-30 | The Curators Of The University Of Missouri | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
KR101907690B1 (ko) * | 2012-04-12 | 2018-10-15 | 한미약품 주식회사 | 비스테로이드성 항염증약물 및 프로톤 펌프 저해제를 포함하는 약제학적 복합제제 및 이의 제조방법 |
-
2020
- 2020-07-14 KR KR1020200087143A patent/KR102608889B1/ko active IP Right Grant
-
2021
- 2021-05-21 BR BR112023000520A patent/BR112023000520A2/pt unknown
- 2021-05-21 WO PCT/KR2021/006381 patent/WO2022014848A1/ko active Application Filing
- 2021-05-21 MX MX2023000645A patent/MX2023000645A/es unknown
- 2021-05-21 CN CN202180061309.XA patent/CN116133651A/zh active Pending
- 2021-05-21 US US18/004,317 patent/US20230248707A1/en active Pending
- 2021-05-21 EP EP21841376.3A patent/EP4166132A4/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0813424B1 (en) * | 1996-01-08 | 2002-11-20 | AstraZeneca AB | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate |
US20040248939A1 (en) * | 2001-08-31 | 2004-12-09 | Masae Sugaya | Stable pharmaceutical compositions comprising acid labile benzimidazoles |
KR20080005575A (ko) | 2005-04-28 | 2008-01-14 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 안정화 조성물 |
KR20150067777A (ko) * | 2013-11-29 | 2015-06-19 | 한미약품 주식회사 | 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제 |
KR20170136771A (ko) * | 2016-06-02 | 2017-12-12 | 동화약품주식회사 | 프로톤 펌프 저해제의 고체분산체 및 이를 포함하는 약제학적 조성물 |
KR101849125B1 (ko) * | 2016-12-12 | 2018-04-16 | 동화약품주식회사 | 프로톤 펌프 저해제를 포함하는 고체 분산체, 이의 제조방법 및 이를 포함하는 구강 붕해정 |
Non-Patent Citations (1)
Title |
---|
See also references of EP4166132A4 |
Also Published As
Publication number | Publication date |
---|---|
EP4166132A1 (en) | 2023-04-19 |
KR20220008688A (ko) | 2022-01-21 |
US20230248707A1 (en) | 2023-08-10 |
MX2023000645A (es) | 2023-02-22 |
CN116133651A (zh) | 2023-05-16 |
KR102608889B1 (ko) | 2023-12-04 |
EP4166132A4 (en) | 2024-05-15 |
BR112023000520A2 (pt) | 2023-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018084627A2 (en) | Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone | |
WO2018070671A1 (ko) | 레날리도마이드의 경구용 정제 조성물 | |
WO2015115750A1 (en) | Stable pharmaceutical composition comprising solifenacin, and method for preparing the same | |
WO2021210929A1 (ko) | 무정형의 엠파글리플로진을 포함하는 안정성이 향상된 신규 약제학적 제형 | |
WO2022014848A1 (ko) | 프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제 및 그의 제조방법 | |
EP4023216A1 (en) | Pharmaceutical composition comprising proton pump inhibitor and antacid | |
WO2020106020A1 (ko) | 이층정제 및 이의 제조 방법 | |
WO2018080104A1 (ko) | 에스오메프라졸 함유 복합 캡슐제 및 그 제조방법 | |
WO2021145676A1 (ko) | 아토르바스타틴 및 에제티미브를 포함하는 정제 | |
WO2021150050A1 (ko) | 프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제 | |
WO2021221288A1 (ko) | 모사프리드 및 프로톤펌프억제제를 함유하는 복합제제 | |
WO2013157840A1 (ko) | 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물 | |
WO2023121054A1 (ko) | 프로톤 펌프 저해제 및 제산제를 포함하는 경구용 복합정제의 제조방법 및 이에 의해 제조된 경구용 복합정제 | |
WO2015102337A1 (ko) | 클로미프라민 함유 약학 조성물 및 이의 제조 방법 | |
EP4070789A1 (en) | Pharmaceutical composite formulation comprising proton pump inhibitor and antacid | |
WO2021075926A1 (ko) | 프로톤 펌프 저해제 및 제산제를 포함하는 약학적 조성물 | |
WO2014163215A1 (ko) | 쓴 맛이 차폐된 약제학적 조성물 | |
WO2018088830A1 (en) | A pharmaceutical composition in a monolithic matrix tablet form comprising chlorthalidone or its salt and amlodipine or its salt and a process for preparing the same | |
WO2022103233A1 (ko) | 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법 | |
WO2022045760A1 (ko) | 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물 | |
WO2017171508A1 (ko) | 안정성 및 용출율이 개선된 타다라필 및 탐수로신 함유 캡슐 복합제제 | |
WO2018030559A1 (ko) | 텔미사르탄을 포함하는 단층정 복합 제제 | |
WO2019245150A1 (ko) | 실로스타졸과 스타틴계약물을 함유하는 약학 조성물 | |
WO2015102331A1 (ko) | 에프로사탄 및 암로디핀을 포함하는 복합제제 및 이의 제조방법 | |
WO2017048033A1 (en) | Pharmaceutical combination preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21841376 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021841376 Country of ref document: EP Effective date: 20230110 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023000520 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112023000520 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230111 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 523442138 Country of ref document: SA |